arrow
M

Markus Moehler

johannes-gutenberg university of mainz
H指数:16
被引数:2,047

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

EORTC-1607-GITCG/ABC-09: Open-label first-line, single-arm phase II study of CisGem combined with pembrolizumab in patients with advanced or metastatic biliary tract cancer

EORTC-1607-GITCG/ABC-09:西吉姆联合帕博利珠单抗治疗晚期或转移性胆道癌的开放标签、单臂II期首线研究

2026-08-010
PRE
Impact of Sex on Efficacy and Safety of 1st-Line Treatment with FOLFIRI plus Cetuximab or Bevacizumab in RAS/BRAF Wildtype Metastatic Colorectal Cancer– A subgroup analysis of the FIRE-3 (AIO KRK-0306) Trial

性別对FOLFIRI联合西妥昔单抗或贝伐珠单抗作为RAS/BRAF野生型转移性结直肠癌一线治疗方案有效性和安全性的影响——FIRE-3 (AIO KRK-0306)试验的亚组分析

2025-11-220
PRE
Comparative efficacy and safety of tislelizumab and other programmed cell death protein 1 inhibitors in first-line treatment of advanced gastroesophageal cancers: a systematic review and network meta-analysis

替雷利珠单抗与其他程序性死亡蛋白1抑制剂在晚期胃食管癌一线治疗中的疗效和安全性比较:一项系统评价和网络Meta分析

2025-10-040
PRE
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

一线Tislelizumab联合化疗治疗程序性死亡配体1表达 ≥ 1% 的晚期胃癌: 原理305的回顾性分析

2025-03-010
OAAI
International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape (vol 27, 649, 2024)
2024-06-170
OAAI
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Tislelizumab加化疗与安慰剂加化疗作为晚期胃或胃食管交界处腺癌的一线治疗: 原理305的随机,双盲,3期试验

2024-05-2810
OA
International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape Bertinoro Workshop, November 2022
2024-04-184
OAAI
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

Futibatinib治疗FGFR2-Rearranged肝内胆管癌

2023-01-19243
OA
Imaging standardisation in metastatic colorectal cancer: A joint EORTC-ESOI-ESGAR expert consensus recommendation
2022-11-010
OA
Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3)
2021-12-0410
OA
Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies
2021-07-2122
OAAI
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

顺铂和5-氟尿嘧啶联合或不联合表皮生长因子受体抑制帕尼单抗治疗不可切除、晚期或转移性食管鳞状细胞癌患者: 一项前瞻性、开放标签、随机III期AIO/EORTC试验 (POWER)

2020-02-0174
OAAI